跳至主要内容
临床试验/CTRI/2018/08/015290
CTRI/2018/08/015290已完成未知

An observational, multicentre, Prospective study to evaluate concordance of detecting EGFR mutation by circulating tumour free DNA versus tissues biopsy in NSCLC (CONCORDANCE) - CONCORDANCE

AstraZeneca Pharma India Ltd0 个研究点目标入组 245 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
245

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Patients who provide written informed consent
  • 2. Patients aged 18 years and older
  • 3. Newly diagnosed patients with Metastatic (stage IV) NSCLC.
  • 4. Histologically confirmed Adenocarcinoma NSCLC patients as per tissue biopsy and the sample sent for EGFR mutation analysis.
  • 5. Patient should be naïve for any systemic treatment (i.e. no chemotherapy or EGFR-TKI)
  • 6. Provision of a routine blood (plasma) sample
  • The prescription of any medicinal product is clearly separated from the decision to include the subject in the study.

排除标准

  • 1. Patient with any medical condition that, in the opinion of the investigator, would interfere with outcome of the study
  • 2. Patient participating in any other interventional clinical study/trial.

研究者

相似试验